Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Get Free Report) traded down 4% during mid-day trading on Thursday . The company traded as low as $24.17 and last traded at $24.64. 1,061,747 shares were traded during trading, a decline of 73% from the average session volume of 3,890,023 shares. The stock had previously closed at $25.68.
Wall Street Analysts Forecast Growth
VKTX has been the topic of several analyst reports. Raymond James lifted their target price on Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Scotiabank began coverage on shares of Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Wednesday, March 26th. Maxim Group cut their price target on Viking Therapeutics from $120.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Finally, Piper Sandler reduced their price objective on shares of Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a research report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $95.18.
Check Out Our Latest Stock Report on VKTX
Viking Therapeutics Stock Performance
The firm has a market cap of $2.39 billion, a PE ratio of -21.28 and a beta of 0.84. The stock has a 50 day simple moving average of $29.32 and a two-hundred day simple moving average of $45.06.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter in the previous year, the business earned ($0.25) earnings per share. Equities research analysts forecast that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Insider Transactions at Viking Therapeutics
In other Viking Therapeutics news, Director Sarah Kathryn Rouan bought 1,240 shares of the business's stock in a transaction dated Monday, March 31st. The shares were acquired at an average cost of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now directly owns 1,240 shares of the company's stock, valued at $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 4.70% of the company's stock.
Institutional Trading of Viking Therapeutics
Hedge funds have recently modified their holdings of the business. Blue Trust Inc. increased its position in shares of Viking Therapeutics by 75.9% in the fourth quarter. Blue Trust Inc. now owns 716 shares of the biotechnology company's stock valued at $29,000 after buying an additional 309 shares in the last quarter. YANKCOM Partnership acquired a new stake in Viking Therapeutics in the 4th quarter worth about $33,000. FIL Ltd boosted its position in shares of Viking Therapeutics by 116.8% in the fourth quarter. FIL Ltd now owns 1,203 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 648 shares during the last quarter. CIBC Private Wealth Group LLC increased its holdings in shares of Viking Therapeutics by 170.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,351 shares of the biotechnology company's stock worth $55,000 after buying an additional 851 shares during the last quarter. Finally, Kapitalo Investimentos Ltda acquired a new stake in Viking Therapeutics during the fourth quarter worth about $63,000. 76.03% of the stock is owned by institutional investors and hedge funds.
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
